先聲藥業(02096.HK)科賽拉地產化申請獲國家藥監局批准

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

先聲藥業(02096.HK)科賽拉地產化申請獲國家藥監局批准

阿思達克 12-28 01:53

先聲藥業(02096.HK)公布，集團腫瘤領域創新藥科賽拉(注射用鹽酸曲拉西利)獲國家藥品監督管理局簽發藥品補充申請批准通知，同意G1將科賽拉藥品生產技術轉讓至海南先聲藥業，並頒發藥品批准文號。未來，科賽拉可由集團位於海南省海口市的生產企業生產，該創新藥的國產化將進一步提升其對內地腫瘤患者的可及性。

先聲藥業(02096.HK)

Relevant Stocks

先聲藥業(02096.HK)

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

先聲藥業(02096.HK)科賽拉地產化申請獲國家藥監局批准

Services

About Us

Agreement Statement